GWS
ABBV icon

Greykasell Wealth Strategies’s AbbVie ABBV Stock Holding History

Greykasell Wealth Strategies’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
5,664
+75
+1% +$16.1K 0.52% 46
2026
Q1 		$1.22M Buy
5,589
+194
+4% +$43K 0.49% 48
2025
Q4 		$1.23M Sell
5,395
-27
-0.5% -$6.15K 0.49% 49
2025
Q3 		$1.26M Buy
5,422
+292
+6% +$59.5K 0.53% 48
2025
Q2 		$952K Buy
5,130
+86
+2% +$16K 0.46% 55
2025
Q1 		$1.06M Buy
5,044
+2
+0% +$389 0.56% 48
2024
Q4 		$896K Buy
+5,042
New +$927K 0.5% 59

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Greykasell Wealth Strategies's ABBV Position: Q2 2026 in Review

Greykasell Wealth Strategies increased its AbbVie (ABBV) stake by 1.3% in Q2 2026, buying an estimated $16.1K and bringing the position to 5,664 shares worth $1.43M. The position accounts for 0.52% of the portfolio, ranked #46.

Greykasell Wealth Strategies first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Greykasell Wealth Strategies held 5,664 shares of AbbVie worth $1.43M as of Q2 2026.
  • Greykasell Wealth Strategies bought 75 AbbVie shares in Q2 2026, an estimated $16.1K.
  • AbbVie made up 0.52% of Greykasell Wealth Strategies's portfolio in Q2 2026, its #46 holding.
  • Greykasell Wealth Strategies first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q2 2026, filed 11 Aug 2026.